Cryo Cell International (CCEL) EBIAT (2016 - 2025)
Cryo Cell International (CCEL) has disclosed EBIAT for 16 consecutive years, with -$3.8 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT fell 105.06% to -$3.8 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$2.4 million, a 704.18% decrease, with the full-year FY2025 number at -$2.4 million, down 704.18% from a year prior.
- EBIAT was -$3.8 million for Q4 2025 at Cryo Cell International, down from $749408.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $2.7 million in Q3 2021 to a low of -$11.2 million in Q4 2023.
- A 5-year average of -$241490.6 and a median of $645254.5 in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: surged 231.49% in 2022, then plummeted 1435.61% in 2023.
- Cryo Cell International's EBIAT stood at -$637192.0 in 2021, then soared by 231.49% to $837822.0 in 2022, then tumbled by 1435.61% to -$11.2 million in 2023, then skyrocketed by 83.36% to -$1.9 million in 2024, then tumbled by 105.06% to -$3.8 million in 2025.
- Per Business Quant, the three most recent readings for CCEL's EBIAT are -$3.8 million (Q4 2025), $749408.0 (Q3 2025), and $355785.0 (Q2 2025).